plumbagin has been researched along with Angiogenesis, Pathologic in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, W; Huang, D; Huo, L; Li, J; Lin, Y; Wei, J; Wei, Y; Zhao, C; Zhong, J | 1 |
| Ketchart, W; Sakunrangsit, N | 1 |
| Dharunya, G; Duraipandy, N; Korapatti, PS; Lakra, R; Syamala Kiran, M | 1 |
| Chen, Y; Li, J; Liu, X; Ma, J; Wei, Y; Yang, Q; Zhang, Y; Zhao, C; Zhao, T; Zhong, J | 1 |
| Chen, Y; Dong, Y; He, L; Lai, L; Lin, Q; Liu, J; Liu, M; Lu, B; Yi, Z; Zhai, D; Zhang, J | 1 |
| Bhattacharya, R; Cao, Y; Couch, FJ; Dutta, S; Elkhanany, A; Iyer, S; Mondal, G; Mukhopadhyay, D; Pal, K; Shridhar, V; Sinha, S; Somasundaram, V; Srinivas, P | 1 |
6 other study(ies) available for plumbagin and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Plumbagin Restrains Hepatocellular Carcinoma Angiogenesis by Stromal Cell-Derived Factor (SDF-1)/CXCR4-CXCR7 Axis.
Topics: Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemokine CXCL12; Human Umbilical Vein Endothelial Cells; Humans; Interleukin-8; Liver; Liver Neoplasms; Naphthoquinones; Neoplasm Invasiveness; Neovascularization, Pathologic; Receptors, CXCR; Receptors, CXCR4; Signal Transduction; Stromal Cells; Vascular Endothelial Growth Factor A | 2019 |
Plumbagin inhibits cancer stem-like cells, angiogenesis and suppresses cell proliferation and invasion by targeting Wnt/β-catenin pathway in endocrine resistant breast cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Female; Humans; Mammary Neoplasms, Experimental; Mice, Inbred BALB C; Naphthoquinones; Neoplastic Stem Cells; Neovascularization, Pathologic | 2019 |
Fabrication of plumbagin on silver nanoframework for tunable redox modulation: Implications for therapeutic angiogenesis.
Topics: Animals; Chick Embryo; Endothelial Cells; Humans; Nanoparticles; Nanotechnology; Naphthoquinones; Neovascularization, Pathologic; Neovascularization, Physiologic; Oxidation-Reduction; Reactive Oxygen Species; Silver | 2019 |
Plumbagin restrains hepatocellular carcinoma angiogenesis by suppressing the migration and invasion of tumor-derived vascular endothelial cells.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Endothelial Cells; Female; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Naphthoquinones; Neoplasm Invasiveness; Neovascularization, Pathologic; Signal Transduction; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2017 |
Plumbagin inhibits tumour angiogenesis and tumour growth through the Ras signalling pathway following activation of the VEGF receptor-2.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chickens; Chorioallantoic Membrane; Human Umbilical Vein Endothelial Cells; Humans; Mice; Mice, Inbred C57BL; Mice, Nude; Naphthoquinones; Neoplasms; Neovascularization, Pathologic; Neovascularization, Physiologic; ras Proteins; Signal Transduction; Tumor Burden; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2012 |
Plumbagin inhibits tumorigenesis and angiogenesis of ovarian cancer cells in vivo.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; BRCA2 Protein; Calcium; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Cisplatin; Endothelial Cells; Female; Glucose Transporter Type 1; Humans; Ki-67 Antigen; Mice; Mice, SCID; Naphthoquinones; Neovascularization, Pathologic; Ovarian Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Random Allocation; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2013 |